Streetbeat News

Revenues

NUWE

SeaStar Medical, a strategic partner of Nuwellis, Inc. (NASDAQ:NUWE), has received an Approvable Letter from the FDA for its pediatric Selective Cytopheretic Device (SCD-PED). The device provides a new therapy option for children with acute kidney injury and sepsis. Nuwellis and SeaStar Medical have an exclusive U.S. license and distribution agreement for Nuwellis to distribute the SCD-PED. The approval of this device will represent a new revenue stream for Nuwellis.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:10 pm

CVLT

Commvault has increased its FY24 revenue outlook to $812M-$822M, up from the previous $805M-$815M, with a consensus of $813.73M. The company expects a 14% YoY growth in total ARR, subscription revenue between $408M and $418M, a 50 to 100 basis points YoY growth in non-GAAP operating margin, and a free cash flow of approximately $170M.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:50 am

CVLT

Commvault has provided guidance for Q3 of fiscal year 2024, expecting total revenues to be between $206M and $210M, which is above the consensus of $205.43M. The company also expects subscription revenue to be between $106M and $110M, and a non-GAAP operating margin of approximately 21%.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:49 am

RGEN

Repligen Corporation has revised its FY23 revenue guidance to $635M-$645M, down from the previous range of $635M-$665M. The new guidance is slightly below the consensus estimate of $644.53M.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:38 am

VNCE

Vince Holding has announced a transformation program that is expected to generate over $30 million in savings over the next three years.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:38 am

XOMA

XOMA Corporation has earned a $5 million milestone payment following the FDA's acceptance of Day One Biopharmaceuticals' New Drug Application (NDA) for Tovorafenib, a treatment for relapsed or progressive pediatric low-grade glioma (pLGG).

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:34 am

SSTK

Shutterstock has increased its FY23 revenue outlook from the range of $852M - $869M to $869M - $886M, which is higher than the estimated $860.82M.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:11 am

SSTK

Shutterstock has increased its FY23 revenue guidance from $4.00 - $4.17 to $4.18 - $4.30, which is above the estimated $4.19.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:10 am

TREE

LendingTree has projected its Q4 revenue to be between $132M and $142M, which is lower than the estimated $144.74M.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:07 am

ARDX

Ardelyx has projected its full-year 2023 U.S. net product revenue for IBSRELA to be between $76.0 and $78.0 million.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:05 am